Fourth cohort completed in Aptahem’s FIH study
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today the completion of an additional cohort in the ongoing double-blinded randomized placebo controlled clinical First in Human (FIH) study.During the course of the study, there have been signs of interesting effects on clinical markers. Therefore, before starting the next cohort, extended analyses will be performed to gain a greater understanding of Apta-1’s clinical significance. These analyses will form an important basis for the further clinical